These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 9469353

  • 1. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R.
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.
    J Natl Cancer Inst; 2008 Apr 16; 100(8):533-41. PubMed ID: 18398095
    [Abstract] [Full Text] [Related]

  • 6. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May 16; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 16; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N.
    J Natl Cancer Inst; 2005 May 04; 97(9):666-74. PubMed ID: 15870437
    [Abstract] [Full Text] [Related]

  • 11. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.
    Woll PJ, Thatcher N, Lomax L, Hodgetts J, Lee SM, Burt PA, Stout R, Simms T, Davies R, Pettengell R.
    J Clin Oncol; 2001 Feb 01; 19(3):712-9. PubMed ID: 11157022
    [Abstract] [Full Text] [Related]

  • 12. Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
    Hastürk S, Kurt B, Kocabas A, Orüç O, Burgut R.
    J Chemother; 1997 Feb 01; 9(1):66-71. PubMed ID: 9106021
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
    Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R, Stephens RJ, Girling DJ.
    J Clin Oncol; 2005 Nov 20; 23(33):8371-9. PubMed ID: 16293867
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis.
    Buchholz E, Manegold C, Pilz L, Thatcher N, Drings P.
    J Thorac Oncol; 2007 Jan 20; 2(1):51-8. PubMed ID: 17410010
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
    Hanauske AR, Korfel A, Perker M, Heinrich B, Schwab G, Graf M, Depenbrock H, Höffken G, Kreuser ED, Thiel E, Zwingers T, Berdel WE.
    Oncology; 1997 Jan 20; 54(5):363-70. PubMed ID: 9260596
    [Abstract] [Full Text] [Related]

  • 19. Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer.
    Iwasaki Y, Nagata K, Nakanishi M, Natuhara A, Kubota Y, Ueda M, Arimoto T, Hara H.
    Chest; 2005 Oct 20; 128(4):2268-73. PubMed ID: 16236883
    [Abstract] [Full Text] [Related]

  • 20. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G.
    J Clin Oncol; 1994 Dec 20; 12(12):2667-76. PubMed ID: 7989942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.